Eversept Partners, LP Dynavax Technologies Corp Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Nov 08, 2023	BUY	$2.94 - $9.1 $208,152 - $644,280	70,800 Added 262.22%	97,800 $867,000
Q2 2020 Aug 13, 2020	BUY	$2.94 - $9.1 $287,532 - $889,980	97,800 New	97,800 $867,000
Q4 2018 Feb 13, 2019	SELL	$8.14 - $13.28 $219,780 - $358,560	-27,000 Closed	0 $0
Q2 2018 Nov 08, 2023	SELL	$15.15 - $20.75 $45,450 - $62,250	-3,000 Reduced 10.0%	27,000 $411,000
Q2 2018 Aug 14, 2018	SELL	$15.15 - $20.75 $45,450 - $62,250	-3,000 Reduced 10.0%	27,000 $412,000
Q1 2018 Nov 08, 2023	BUY	$14.65 - $19.9 $439,500 - $597,000	30,000 New	30,000 $596 Million
Q1 2018 May 14, 2018	BUY	$14.65 - $19.9 $439,500 - $597,000	30,000 New	30,000 $596,000

288

131M

507K

374K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.74B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.